Remogliflozin etabonate

Remogliflozin etabonate (INN/USAN) is a proposed drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ('NASH') and type 2 diabetes. Remogliflozin was discovered and developed by the Japanese company Kissei Pharmaceutical, and later developed by GlaxoSmithKline and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt. Remogliflozin was commercially launched first in India by Glenmark in May 2019. Remogliflozin etabonate (INN/USAN) is a proposed drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ('NASH') and type 2 diabetes. Remogliflozin was discovered and developed by the Japanese company Kissei Pharmaceutical, and later developed by GlaxoSmithKline and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt. Remogliflozin was commercially launched first in India by Glenmark in May 2019. Remogliflozin etabonate was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels. Remogliflozin etabonate has been studied at doses up to 1000 mg. A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated. Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.